This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants (NEOBRAIN)

This study has been completed.
European Commission
Information provided by:
Hannover Medical School Identifier:
First received: October 12, 2007
Last updated: June 22, 2011
Last verified: June 2011
NEOBRAIN brings together small and medium sized enterprises (SMEs), industry and academic groups devoted to the diagnosis, management, and neuroprotection in newborns with perinatal brain damage. The focus of NEOBRAIN is to identify strategies prevention of brain damage mainly observed in preterm newborns. (Copy from

Brain Damage, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Neonatal Estimation Of Brain Damage Risk And Identification of Neuroprotectants

Further study details as provided by Hannover Medical School:

Primary Outcome Measures:
  • Brain white matter damage (WMD, defined by MRI ,US, EEG) [ Time Frame: during stay in NICU and until discharge ]

Secondary Outcome Measures:
  • Developmental assessment [ Time Frame: at 2 years of age ]

Biospecimen Retention:   Samples With DNA
whole blood, urine

Estimated Enrollment: 600
Study Start Date: October 2007
Study Completion Date: October 2010

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Preterm newborns with a gestational age < 28wks

Inclusion Criteria:

  • Gestational age < 28 weeks
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00544895

Medizinische Universität Innsbruck
Innsbruck, Austria, 6020
Hôpital Robert Debré
Paris, France, F-75019
Charité, Campus Virchow Klinikum
Berlin, Germany, 13353
Universität Duisburg-Essen
Essen, Germany, 45122
Hannover Medical School
Hannover, Germany, 30625
Fondazione I.R.C.C.S Ospedale Maggiore Policlinico MA.RE.
Milano, Italy
Azienda Ospedaliera Universitaria Senese
Siena, Italy, 53100
Wilhelmina Children's Hospital
Utrecht, Netherlands, 3508 AB
Perinatal Center
Gothenburg, Sweden, 41685
University Hospital
Lund, Sweden, 22185
Academic Children's Hospital
Uppsala, Sweden, 75185
Hôpital des Enfants
Geneva, Switzerland, 1211
Sponsors and Collaborators
Hannover Medical School
European Commission
Study Director: Olaf Dammann Medical School Hannover
  More Information

Responsible Party: Prof. Dr. med. Olaf Dammann, Perinatal Infectious Disease Epidemiology Unit - Medical School Hannover Identifier: NCT00544895     History of Changes
Other Study ID Numbers: LSHM-CT-2006-036534
Study First Received: October 12, 2007
Last Updated: June 22, 2011

Additional relevant MeSH terms:
Brain Injuries
Brain Damage, Chronic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs processed this record on September 19, 2017